Innovation1 Biotech Inc. (IVBT)

[captainscotty]

#GMVP: SAD SAP... WE MISS U

[captainscotty]

#GMVP: How does that crow taste...

[lflhdy]

LOL

[Sheriff2]

OMG STFU!!

[Digger 9197]

Like you said dman was going to trips

[Digger 9197]

I will ignore you and have been .

[Digger 9197]

he’s been doing this on dman boards for months . Ignore him . Check it out over 7000 negative posts

[DJN]

PAIR MADE IN HEAVEN LMFAO!!! TOO FUNNY!!!

[DJN]

1 TURD SIGNS AN AGREEMENT WITH ANOTHER TURD LMFAO!!!

[SeanP619]

https://www.otcmarkets.com/stock/DMAN/news/Demand-Brands-DMAN-Signs-Distribution-Agreement-for-Gridiron-MV-TM-GMVP?id=217679

[richard hill]

Stepped on this garbage

[richard hill]

Criminals. Scam all day

[makinezmoney]

$GMVP: CBD Hemp Water

[SupremeFoscheem]

This company needs to partner with a distributor to get their products on retail shelves.

[Robthoma]

Has anyone noticed, Gridiron has added a new website and new products this week. Looking good!

[Robthoma]

As always, do your own DD.

Your own stock trading is 100% on you and no one else but you. Thank You

[Robthoma]

It takes time to build a strong foundation. This is a micro cap company with a great future in the emerging CBD market. I keep adding to my position here.

[Robthoma]

This was a well done presentation on canibus business growth.
https://pro.nicinvestors.com/p/CIRLNC39V/LCIRUA64/?SID=1120DTAemail&h=true

[SupremeFoscheem]

Great products with credible, powerful endorsements. Need to get on retail shelves. There are are several professional marketing firms and established firms with which to partner. 100% of no growth is no growth 50% of 50% growth is growth.

[SupremeFoscheem]

Grid Iron Company: May I suggest you hire either a sales staff or negotiate with GNC, The Vitamin Shop, and franchised gyms to get products on their shelves?

[SupremeFoscheem]

Come on Grid Iron! Break through that Resistance.

[SupremeFoscheem]

Come on Grid Iron! Break through that Resistance.

[SupremeFoscheem]

Come on Grid Iron! Break through that Resistance.

[SupremeFoscheem]

Go Grid Iron! Yeah! Pump it! Up! Up! Up!

[SupremeFoscheem]

May have a pulse...up 5.5%...

[Robthoma]

AllNewsPress Releases
ACCESSWIRE•4 days ago
Gridiron BioNutrient(TM) Begins Trading on the OTCQB Venture Market
SPOKANE, WA / ACCESSWIRE / September 11, 2018 / Gridiron BioNutrients™ (GMVP), a nutraceutical innovator specializing in Cannabidiol ("CBD") health and wellness products to the individual and sports and fitness markets is pleased to announce that OTC Markets have approved the Company's stock for listing on the OTCQB Venture Market. "Up-Listing from the OTC Pink Open Market tier to the OTCQB Venture Market supports the Company's goal of providing a high level of financial and corporate disclosure that is required for the listing, which in turn, demonstrates our continued commitment to our shareholders by increasing transparency and credibility.

[SupremeFoscheem]

I saw those, and I too have been holding GMVP several months. I sold some but not all shares in March. I think the CBD drink market potential is huge and I continue to watch this stock closely. I am sure you are aware of the Constellation Brands and Molsolm plans to enter the CBD drink market. I would like to see a major bottling company/distribuor partner with this company, or even acquire it.

[Robthoma]

I have been researching this company for five months
I don't check back here very often.
Grays Peak now owns 85million shares of GMVP
Largest share owner to date.
Totall outstanding shares are 132,866,000
Timothy Orr owns now 20 million shares. Up 3 mill
Public shares are 27,861,000 mill

Financing is now strong with new offering of shares
132,866,000 Total outstanding shares
20,000,000 Tim Orr
27,000,000 float
Aug 10 quarter report
August 10, 2018. The Company received $1,006,000, net of a 5% percent original issue discount for the Units, at closing of the sale of the Units.
 


Current Report Filing (8-k)
Date : 08/16/2018 @ 2:50PM
Source : Edgar (US Regulatory)
Stock : Gridiron Bionutrients, Inc. (PC) (GMVP)
Quote : 0.0659  0.00615 (10.29%) @ 4:00PM

Current Report Filing (8-k)
Tweet


Print
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 10, 2018
 

GridIron BioNutrients, Inc.
(Exact name of registrant as specified in its charter)

 
Nevada
(State or other jurisdiction of incorporation)
 
000-55852
(Commission File Number)
 
36-4797193
(IRS Employer Identification No.)
 
1119 West 1st Ave., Ste. G
Spokane, Washington 99021
(Address of principal executive offices)(Zip Code)
 
[phone]
Registrant’s telephone number, including area code
 
___________________________________________
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 





 
 

 
 

Item 1.01 Entry into a Material Definitive Agreement.
 
Securities Purchase Agreement
 
Effective July 30, 2018, GridIron BioNutrients, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with two (2) accredited investors (the “Purchasers”) pursuant to which the Company agreed to sell and the Purchasers agreed to purchase, subject to certain customary closing conditions, an aggregate of $1,060,000 convertible preferred stock units (the “Units”). Each Unit consists of one share of Series A Preferred Stock (the “Series A Preferred Stock”) and one warrant (a “Warrant”). The Securities Purchase Agreement contains customary representations, warranties, and covenants by, among, and for the benefit of the parties. The Company closed on the sale of the Units on August 10, 2018. The Company received $1,006,000, net of a 5% percent original issue discount for the Units, at closing of the sale of the Units.
 
Each share of Series A Preferred Stock has a dividend of 5% per annum, has a liquidation preference senior to all other capital stock of the Company, and is convertible at any time, at the election of the holder of the Series A Preferred Stock, into one share of common stock at a conversion price of $0.125 per share, which conversion price is subject to adjustment for a term of two (2) years for stock splits, stock dividends, combinations, or similar events, and has full ratchet anti-dilution protection. Additionally, each holder of Series A Preferred Stock and has voting rights equal to that number of shares of common stock into which such holder’s shares of Series A Preferred Stock would be convertible on the record date for the vote or consent of stockholders, and shall otherwise have voting rights and powers equal to the voting rights and powers of the common stock. The Company has a right to purchase any outstanding shares of Series A Preferred Stock, with 20 days’ notice, at (i) a 115% premium before 180 days after the closing, and (ii) a 125% premium following the 181st day after closing. The holders of shares of Series A Preferred Stock have a right to participate in 50% of all financings of the Company, except for certain exempt offers and sales, for a period of two (2) years following the closing or if there are no shares of Series A Preferred Stock outstanding.
 
Each Warrant is convertible into one share of common stock at a conversion price of $0.165 per share, for a term of three years, and contains a cashless exercise feature, if such Warrant not registered in a registration statement. The conversion price of $0.165 is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. The Company may call the warrants if shares of the Company’s common stock trades at a volume weighted average price of not less than $0.30 for ten (10) consecutive trading days and are covered by an effective registration statement, where the average daily volume of the common stock for the previous ten trading days has been greater than $75,000.
 
Registration Rights Agreement
 
In connection with the offer and sale of the Units, the Company and the Purchasers entered into a Registration Rights Agreement dated July 30, 2018, pursuant to which the Company is obligated to register all of the shares of common stock underlying the Series A Preferred Stock and the Warrants, which amounts to 16,960,000 shares of common stock amounts as of the date of filing of this Form 8-K.
 
The foregoing description of the Securities Purchase Agreement, the Registration Rights Agreement, the Warrant, Certificate of Amendment dated July 16, 2018, Certificate of Amendment dated August 1, 2018, Certificate of Designation dated July 31, 2018, and Certificate of Correction dated August 1, 2018, are qualified in its entirety by reference to the full text of such documents, copies of which are filed as Exhibit 10.1, Exhibit 10.2, Exhibit 4.1, Exhibit 3.1.1, Exhibit 3.1.2, Exhibit 3.1.3 and Exhibit 3.1.4, respectively, to this Current Report on Form 8-K and which are incorporated by reference herein in their entirety.
 

 
2

 
 

 
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
Amendments to Articles of Incorporation
 
On July 16, 2018, the Board of Directors and one (1) stockholder adopted and approved a resolution to effect an amendment to our Articles of Incorporation to authorize the creation of 5,000,000 shares, designated as our Preferred Stock. On July 16, 2018, the Company filed a Certificate of Amendment to its Articles of Incorporation creating 5,000,000 shares of preferred stock.
 
On August 1, 2018, the Board of Directors and one (1) stockholder adopted and approved a resolution to effect an amendment to our Articles of Incorporation to authorize the creation of 25,000,000 shares, designated as our Preferred Stock. On August 1, 2018, the Company filed a Certificate of Amendment to its Articles of Incorporation creating 25,000,000 shares of preferred stock.
 
On July 30, 2018, the Board of Directors of the Company authorized the designation of 9,000,000 shares of Series A Preferred Stock. On July 31, 2018, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada, creating 900,000 shares of Series A Preferred Stock. The material materials terms, powers, preferences and rights of the Series A Preferred Stock are disclosed in Item 1.01 to this Current Report on Form 8-K and incorporated by reference into this Item 5.03.
 
On August 1, 2018, the Company filed a Certificate of Correction, correcting the number of shares designated a Series A Preferred Stock, as printed in the Certificate of Designation, from 900,000 to 9,000,000.
 
Principal effects of the creation of “blank check” preferred stock.
 
The Certificate of Amendment filed with the Secretary of State of the State of Nevada on July 16, 2018, and the Certificate of Amendment, filed with the Secretary of State of the State of Nevada on August 1, 2018 on August 1, 2018 are collectively referred to herein as the “Preferred Stock Amendment.” Subject to the provisions of the Preferred Stock Amendment and the limitations prescribed by law, our Board of Directors would be expressly authorized, at its discretion, to adopt resolutions to issue shares, to fix the number of shares and to change the number of shares constituting any series and to provide for or change the voting powers, designations, preferences and relative, participating, optional or other special rights, qualifications, limitations or restrictions thereof, including dividend rights (including whether the dividends are cumulative), dividend rates, terms of redemption (including sinking fund provisions), redemption prices, conversion rights and liquidation preferences of the shares constituting any series of the Preferred Stock, in each case without any further action or vote by our stockholders. Our Board of Directors would be required to make any determination to issue shares of Preferred Stock based on its judgment as to what is in our best interests and the best interests of our stockholders. The Preferred Stock Amendment will give our Board of Directors flexibility, without further stockholder action, to issue Preferred Stock on such terms and conditions as our Board of Directors deems to be in our best interests and the best interests of our stockholders.
 
The authorization of the Preferred Stock will provide us with increased financial flexibility in meeting future capital requirements. It will allow Preferred Stock to be available for issuance from time to time and with such features as determined by our Board of Directors for any proper corporate purpose. It is anticipated that such purposes may include, without limitation, exchanging Preferred Stock for common stock, the issuance for cash as a means of obtaining capital for our use, or issuance as part or all of the consideration required to be paid by us for acquisitions of other businesses or assets.
 
The issuance by us of Preferred Stock could dilute both the equity interests and the earnings per share of existing holders of our common stock. Such dilution may be substantial, depending upon the amount of shares issued. The newly authorized shares of Preferred Stock could also have voting rights superior to our common stock, and therefore would have a dilutive effect on the voting power of our existing stockholders.
 
Any issuance of Preferred Stock with voting rights could, under certain circumstances, have the effect of delaying or preventing a change in control of our Company by increasing the number of outstanding shares entitled to vote and by increasing the number of votes required to approve a change in control of our Company. Shares of voting or convertible Preferred Stock could be issued, or rights to purchase such shares could be issued, to render more difficult or discourage an attempt to obtain control of our Company by means of a tender offer, proxy contest, merger or otherwise. The ability of our Board of Directors to issue such shares of Preferred Stock, with the rights and preferences it deems advisable, could discourage an attempt by a party to acquire control of our Company by tender offer or other means. Such issuances could therefore deprive our stockholders of benefits that could result from such an attempt, such as the realization of a premium over the market price that such an attempt could cause. Moreover, the issuance of such shares of Preferred Stock to persons friendly to our Board of Directors could make it more difficult to remove incumbent managers and directors from office even if such change were to be favorable to stockholders generally.
 

 
3

 
 

 
The Company has (i) no present plans or commitments for the issuance or use of the Preferred Stock in connection with any financing, and (ii) no present plans, proposals or arrangements, written or otherwise, at this time to issue any of the Preferred Stock in connection with a merger, share exchange or acquisition.
 
Anti-takeover Effects
 
The Preferred Stock Amendment will provide us with shares of Preferred Stock which would permit us to issue additional shares of capital stock that could dilute the ownership of the holders of our common stock by one or more persons seeking to effect a change in the composition of our Board of Directors or contemplating a tender offer or other transaction for the combination of GridIron BioNutrients with another company. The creation of the Preferred Stock is not being undertaken in response to any effort of which our Board of Directors is aware to enable anyone to accumulate shares of our common stock or gain control of GridIron BioNutrients. The purpose of the creation of the Preferred Stock is to grant us the flexibility to issue our equity securities in the manner best suited for our Company, or as may be required by the capital markets. However, we presently have no plans, proposals, or arrangements to issue any of the newly authorized shares of Preferred Stock for any purpose whatsoever, including future acquisitions and/or financings.
 
Other than the creation of the “blank check” Preferred Stock, our Board of Directors does not currently contemplate the adoption of any other amendments to our Articles of Incorporation that could be construed to affect the ability of third parties to take over or change the control of GridIron BioNutrients. While it is possible that management could use the additional authorized shares of common stock or Preferred Stock to resist or frustrate a third-party transaction that is favored by a majority of the independent stockholders, we have no intent, plans or proposals to use the newly created Preferred Stock as an anti-takeover mechanism or to adopt other provisions or enter into other arrangements that may have anti-takeover consequences.
 
While the creation of the “blank check” Preferred Stock may have anti-takeover ramifications, our Board of Directors believes that the financial flexibility offered by such corporate actions will outweigh the disadvantages. To the extent that these corporate actions may have anti-takeover effects, third parties seeking to acquire us may be encouraged to negotiate directly with our Board of Directors, enabling us to consider the proposed transaction in a manner that best serves the stockholders’ interests.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Number

Description
 


3.1.1

Certificate of Amendment to Articles of Incorporation dated July 16, 2018.
3.1.2

Certificate of Amendment to Articles of Incorporation dated August 1, 2018.
3.1.3
 
Certificate of Designation dated July 31, 2018.
3.1.4
 
Certificate of Correction dated August 1, 2018.
4.1

Form of Warrant, dated July 30, 2018.
10.1
 
Form of Securities Purchase Agreement, dated July 30, 2018
10.2
 
Form of Registration Rights Agreement, dated July 30, 2018
 

 
4

 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
GridIron BioNutrients, Inc.




Date: August 16, 2018
By:
/s/ Timothy Orr

 
Name:
Timothy Orr

 
Title:
President

 
 

5


GridIron BioNutrients, Inc.
(Exact name of registrant as specified in its charter)






2



3


Number Description

3.1.1 Certificate of Amendment to Articles of Incorporation dated July 16, 2018.
3.1.2 Certificate of Amendment to Articles of Incorporation dated August 1, 2018.
3.1.3 Certificate of Designation dated July 31, 2018.
3.1.4 Certificate of Correction dated August 1, 2018.
4.1 Form of Warrant, dated July 30, 2018.
10.1 Form of Securities Purchase Agreement, dated July 30, 2018
10.2 Form of Registration Rights Agreement, dated July 30, 2018

4


GridIron BioNutrients, Inc.

Date: August 16, 2018 By: /s/ Timothy Orr
Name: Timothy Orr
Title: President
5
Gridiron BioNutrients, Inc. (USOTC:GMVP)
Historical Stock Chart
1 Year : From Aug 2017 to Aug 2018
Gridiron BioNutrients, Inc. (USOTC:GMVP)
Intraday Stock Chart
Today : Friday 17 August 2018

Latest GMVP Messages

SupremeFoscheem Mon Aug 6, 2018 9:50 AM (10 days ago)
GMVP looking like Flucuations today. Also, FlukuAmericans, FlucuEuropeans, Flucu SupremeFoscheem Fri Aug 3, 2018 10:32 AM (13 days ago)
I hope athletes who drink this stuff move SupremeFascheem Tue Jul 31, 2018 12:02 PM (16 days ago)
Hey! I notice that, according to E-Trade, there SupremeFoscheem Fri Jul 27, 2018 9:37 AM (20 days ago)
Hey, up today! Not adding shares now Robthoma Thu Jul 26, 2018 7:52 PM (21 days ago)
II am still cost averaging. SupremeFoscheem Tue Jul 17, 2018 12:57 PM (30 days ago)
Any last words? Tobyray Wed Jun 6, 2018 4:28 PM (71 days ago)
They took our money and left us holding Robthoma Tue May 29, 2018 3:15 PM (79 days ago)
Breakout is happening Robthoma Fri Apr 13, 2018 2:13 PM (125 days ago)
Trump commits to protect states on marijuana keepemcloser Mon Apr 9, 2018 7:38 PM (129 days ago)
We as a Society need advances like this

See More Posts on GMVP Message Board
Bookmark With :
?

?

?

?

?

?

?

?

?

?

?

?

?

?




Your Recent History
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


CREATE A CUSTOM STOCK WATCHLIST >

LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

?
?

?
Sponsored Financial Content
?
See How Data and Tech Innovation are Transforming Credit Teams
Dun & Bradstreet
?
Your ticket to the Forex Market
FOREX.com
?
Internet 5x The Speed of DSL. Bundle Services for Extra Savings.
Comcast® Business




© 2018 InvestorsHub.com, Inc.
* • About
* Investor Relations
* About Us
* Terms of Service
* Privacy Policy
* Advertise With Us
* Data Accreditations
* Disclaimer
* Help
* FAQ
* Handbook
* Q&A Forum
* Contact Us
* Tutorials
* Educational
* Educational Channel
* Stock Market 101
* Educational Videos
* Investor Help Forum
* Personal Finance Q&A
* More
* Corporate Solutions
* iHub on Facebook
* iHub on Twitter
* iHub iPhone/iPad App
* iHub Android App
* iHub BlackBerry App
* iHub NewsWire





?

[SupremeFoscheem]

GMVP looking like Flucuations today. Also, FlukuAmericans, FlucuEuropeans, FlucuAfricaners!

[SupremeFoscheem]

I hope athletes who drink this stuff move better than its stock.

[SupremeFascheem]

Hey! I notice that, according to E-Trade, there have been no "Insider" stock purchases. None of Gridiron BioNutrients' officers bought any shares in the past five years. Should I be concerned about this stock?

[SupremeFoscheem]

Hey, up today! Not adding shares now but just for entertainment, check out the Stochs.Technicals suggest increase. LOL.

[Robthoma]

II am still cost averaging.

[SupremeFoscheem]

Any last words?

[Tobyray]

They took our money and left us holding the bag

[Robthoma]

Breakout is happening

[Robthoma]

Trump commits to protect states on marijuana

Apr. 13, 2018 1:55 PM ET |By: Stephen Alpher, SA News Editor
Colorado Senator Cory Gardner says the president will back congressional efforts to protect states which have legalized grass.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=gmvp&postid=27881139#Dlavz7WXferKfFrt.99

[keepemcloser]

We as a Society need advances like this and it is time to get rid of outdated laws that waste time money and mostly Lives.

[Zboricua]

Promo going into full effect

[Robthoma]

JOSH KAPLAN
December 28, 2017
The Top CBD Cannabis Studies of 2017
The past year was important for proponents of medical cannabis. Those seeking to remove cannabis’ Schedule I status are now armed with even more evidence for its medicinal and wellness benefits from a combination of human and rodent studies. From benefits in epilepsy, autism, and beyond, here are some of 2017’s biggest medical cannabis news stories. This installment covers insights relating to CBD, but tune in to the second part of this series for more discoveries uncovered in 2017.
Cannabidiol (CBD) passes stage 3 clinical trial for treatment of epilepsy in children.
Source: New England Journal of Medicine, May 2017
This one was big. One of the greatest limitations in the medicinal cannabis field is the lack of randomized double-blinded studies, the standard in clinical research. This limitation is often the basis of the opposition’s argument that there’s no strong evidence to support clinical cannabis use. But that argument was undermined by the successful trial of CBD treatment in children with epilepsy.
CBD reduced the median number of seizures each month by 39% compared to 13% for placebo-treated patients.
Scientists studied the effect of CBD (Epidolex developed by GW Pharmaceuticals) on epileptic seizures in patients with Dravet syndrome. Dravet syndrome is a severe epileptic childhood disorder caused by genetic mutation that reduces brain inhibition and leads to frequent and uncontrollable seizures. Traditional anti-epileptic medications are largely ineffective at preventing seizures in Dravet syndrome, but anecdotal reports from parents of children with the condition suggest that CBD-rich cannabis effectively reduces seizures.
The researchers found that orally-consumed CBD oil over a 14-week treatment period was an effective anti-epileptic treatment in these patients, reducing the median number of seizures each month by 39% compared to 13% for placebo-treated patients. Further, these anti-epileptic benefits were achieved with only minimal side effects, of which diarrhea and drowsiness were the most reported. While these could be problematic in their own right, they beat having seizures and many of the side-effects from traditional anti-epileptic strategies.

RELATED STORY
Cannabis and Epilepsy Treatment
Because CBD was used as an add-on therapy to the patients’ other anti-epileptic medications, one of the limitations of this study was not being to identify if CBD on its own reduced seizures, or if its anti-epileptic abilities were through interaction with other medications.
Nonetheless, this study’s double-blinded design was a substantial improvement over earlier assessments and benefited from a large sample size (61 received CBD, and 59 received placebo). Previous CBD trials found that it effectively reduced seizures in other drug-resistant forms of epilepsy, but the conclusions of these studies were weakened by their open-label nature, which allowed patients and doctors to be aware they were taking CBD and permitted bias.
This is the largest and most successful clinical trial to-date to demonstrate the medicinal benefits of CBD, and it will likely convince many clinicians to consider CBD for treating the 20% of epileptic disorders that are poorly controlled by traditional anti-epileptic drugs.
Add autism to the list of CBD’s medicinal benefits.
Source: Proceedings of the National Academy of Sciences, October 2017
Autism is often the result of too little inhibition in the brain, which leads to heightened sensitivity to stimuli (such as lights, sounds, touch, and smells) and abnormal social behavior. Epilepsy can also result from too little brain inhibition, and it’s common for individuals on the severe end of the autism spectrum to also have epilepsy. Scientists then may study both epilepsy and autism that are caused by the same DNA mutation.
Soon after the exciting clinical data demonstrating CBD’s effectiveness at reducing seizures in children with drug-resistant epilepsy, University of Washington scientists published a report demonstrating CBD’s effectiveness in a mouse model of epilepsy and autism.

RELATED STORY
How Does Cannabis Consumption Affect Autism?
As described above, one of the limitations of the clinical study of CBD in patients with Dravet syndrome is that, for ethical reasons, patients remained on their anti-epileptic medications; CBD was used as an add-on therapy, leading skeptics to posit that CBD’s anti-epileptic effects were in fact mediated by an interaction between CBD and other medications. To assess if CBD had anti-epileptic effects on its own in drug-resistant epilepsy, scientists tested CBD’s effects in mice with the same genetic mutation as humans with Dravet syndrome.
CBD increased the mice’s preference for spending time interacting with other mice and reduced the number of social anxiety-like behaviors.
In these epileptic mice, scientists confirmed that CBD, by itself, was sufficient to reduce seizures. Further, it was revealed that CBD rescues deficits in brain inhibition by blocking the activity of a brain receptor called GPR55. Now that CBD’s anti-epileptic effects are better understood in the brain and have been observed in humans and rodents, there’s an especially compelling case for clinical use of CBD in treating drug-resistant epilepsies.
But it doesn’t end there.
In addition to epilepsy, children with Dravet syndrome and other epileptic disorders often have autism. Unfortunately, the phase III clinical trial of CBD’s efficacy on seizures wasn’t able to simultaneously address autism-like social deficits in these individuals. However, University of Washington scientists looked at CBD’s impact on autistic-like social deficits, and they revealed that CBD normalizes social behavior in mice. CBD increased the mice’s preference for spending time interacting with other mice and reduced the number of social anxiety-like behaviors. Critically, this improvement occurred even after the mice had undergone numerous seizures, which highlights its medicinal potential at any age.

RELATED STORY
CBD and the Brain: What Does It Do and What Is It Good For?
This was the first controlled study to demonstrate CBD’s ability to treat autistic-like social behaviors. CBD’s ability to improve symptoms of autism, even if it’s used in late developmental stages or adulthood, provides strong justification for the first human clinical trial to test cannabis oil in the treatment of autism, which is currently being conducted in 120 Israeli patients.
Addressing 2016’s biggest health scare: Does CBD turn into THC in our stomach?
Source: Journal of Pharmaceutical and Biomedical Analysis, available online December 2017
In 2016, a report claiming that CBD gets converted to THC in the stomach raised fear among proponents and patients. CBD has been emerging as a powerful medicinal tool for treating numerous disorders in children, adolescents, and adults. However, if CBD were to be converted to THC, this could negatively impact brain development in children and adolescents and induce side effects in adults.
Since that report, many have stated the obvious: If CBD gets converted to THC, then patients that consume large doses of CBD should experience THC-like effects. But they don’t! This simple observation prompted many to speculate that the conversion of CBD to THC was an artifact of the experimental conditions which were conducted in a petri dish and not a living creature.
To address whether CBD gets converted to THC in a living animal, scientists in Italy dosed rats with a high concentration of CBD and measured cannabinoids in the blood. Neither THC nor its metabolites were detected. These findings support the conclusions from behavioral studies in humans and animals that CBD does not convert to THC in the stomach in any meaningful amount. So in 2018, rest assured that you can attain CBD’s medicinal benefits without the potential risk of THC exposure.
Eager for more of 2017’s most compelling cannabis research? Stay tuned for part two, where we dive into more good news brought forth by the scientists and researchers working boldly in the cannabis space.
Lead Image: Kkolosov/iStock
JOSH KAPLAN
AUTISM
BEST OF 2017
CBD
CBD OIL
EPILEPSY
RESEARCH
SCIENCE

Josh Kaplan
Josh Kaplan earned his Ph.D. in behavioral neuroscience from Oregon Health & Science University in 2015. He is currently a freelance writer and a senior fellow at the University of Washington conducting medicinal cannabis research.
NEXT CHAPTER
The Top Medical Cannabis Studies of 2017

[$$DodgerTrader]

200k pay promotion starting today.

[MRJOJO58]

Stock of the Week my Arse,lol

[Robthoma]

https://www.investopedia.com/terms/t/triplebottom.asp

[Robthoma]

BD Hemp Oil: WADA Approved for Amateur & Professional Athletes
Rate this article
image: http://www.stockhouse.com/Stockhouse/images/stars-mask.png


The World Anti-Doping Agency has ruled that Cannabidiol from hemp is safer than cough medicine.
Canadian rower and Sports Hall-of-Famer, Silken Laumann, learned the hard way how the use of a banned performance-enhancing substances can damage or even end an athlete’s career Laumann was stripped of her quadruple sculls gold medal from the 1995 Pan American Games after testing positive for pseudoephedrine, a substance banned by the World Anti-Doping Agency (WADA). Laumann’s case is particularly unsettling because she inadvertently took the drug via a cold medication.  Yet, athletes are always looking for a competitive edge to build their speed, strength and endurance while staying healthy—Lance Armstrong fiasco aside.

The World Anti-Doping Agency was created to establish the global standard via the World Anti-Doping Code, whose provisions are enforced by the UNESCO International Convention against Doping in Sport. The aims of the Council of Europe Anti-Doping Convention and the United States Anti-Doping Agency are also closely aligned with those of WADA. In November 2007, more than 600 sports organizations adopted the code, including the summer and winter games and the Fédération Internationale de Football Association (FIFA).

2018 will be a major platform for competitive sports after the winter games in South Korea and the 2018 FIFA World Cup in Russia.  And with the trend towards global acceptance and legalization of CBD-Hemp Oil extracts and products, much of the dialog centers around the use of cannabinoids and sports.

While marijuana, and the psychoactive component THC derived from it, remains a prohibited substance, WADA officially removed cannabidiol (CBD) derived from hemp oil, from its Prohibited Substances List as of January 1, 2018.  This is significant as WADA harmonizes global policy as the strictest anti-doping rules in all competitive sports. It is the bellwether for amateur sports leagues such the NCAA, and professional sports organizations such as the NFL, NHL, MLB and the NBA.
CBD is a non-psychoactive cannabinoid studied to be a powerful anti-inflammatory, antioxidant and neuroprotectant. Ongoing research supports that CBD is known to optimize daily performance, treat chronic pain and inflammation-based conditions and help athletes to recover from injuries. WADA reports "cannabidiol is no longer prohibited as it does not mimic the effects of THC and clarifies that marijuana is "still a prohibited substance".

In the case of Asia, CBD from marijuana is currently prohibited across all major Asian countries. However, the legal use of naturally occurring cannabinoids from hemp oil is still to be determined in South Korea. In the United States, marijuana is federally illegal, but hemp provides a legal option for licensed clinicians.  WADA's new ruling now opens CBD up to sports medicine practitioners such as physiotherapists, kinesiologists and team physicians.

Another concerning issue for many athletes, particularly in the NFL and NHL, is repeated head injuries and concussion, which can have lasting effects over the lifetime of an athlete. CBD is considered viable to treat and even prevent chronic traumatic encephalopathy (CTE), which is a degenerative brain disease found in athletes who have a history of trauma to the brain. In one neuropathology study, 99% of former NFL players tested positive for CTE.  The NFL endorses studies of opiate-free cannabinoids to treat pain and inflammation, but currently suspends players for testing positive for THC, and has yet to respond to WADA's new rules on CBD.

Recent CBD-focused clinical trials found on www.pubmed.gov show efficacy of CBC as an anti-inflammatory and neuroprotectant (a shock absorber against concussions). Inflammation control is also key as it is widely known as the root cause of major disorders and diseases.

One company that is specifically targeting the use of CBD for sports and active lifestyles is Phivida Holdings Inc. (CNX: C.VIDA, OTC:PHVAF, Forum). According to the company’s CEO, Phivida seeks to “equip, empower and educate professional athletes, and active professionals with the option of using CBD-Hemp oil extract as an alternative to opiate-based pain killers.” To that end, the company recently formed a partnership with like-minded Superheroes Management (SHM) sports marketing agency, and signed World Surfing League Pro Surfing star, Ms. Malia Manuel as its first brand ambassador. 

Phivida, listed on the Canadian Securities Exchange as “VIDA”, is developing and bringing to market its branded CBD hemp oil extracts, CBD infused functional foods and beverages, and higher potency CBD tinctures, vitamin shots and topicals for healthcare practitioners.  The company is also sponsoring leading edge clinical research on the efficacy and bioavailability (the degree and rate at which an administered drug is absorbed by the body's circulatory system) of its hemp-derived CBD products.  Phivida's full-spectrum CBD hemp oil extract from permitted hemp farms is rich in CBD, but less than 0.3% THC, for full compliance with WADA and US federal laws.

Phivida is actively pursuing partnerships with leagues around the world. working as WADA’s January 1st ruling has made Phivida’s CBD-Hemp Oil infusions safe for use by athletes everywhere, for the first time in the history of competitive sports.
There is a lot more research and education ahead to validate the use of CBD in sports. Meanwhile, athletes can now feel at ease using hemp derived CBD products to gain that competitive edge without risking their future.
Tags:
HEALTHCARE

Interested in these industries and sectors?
Receive investor kits and email updates from Stockhouse and directly from these companies.
Healthcare
Select All None

Relevium Technologies Inc.

Beleave Inc
Technology
Select All None

Alternate Health Corp.
Metals & Mining
Industrials
Technology

I consent to receiving investment related electronic messages from Stockhouse and the companies selected. I may withdraw my consent at any time.
Submit

Comments
No comments yet. Be first to comment!


Leave a Comment
Subscribe to comments for this article

[DoubleJackie]

Absolute scam this is. Mega bag holders here.

[DoubleJackie]

[Robthoma]

More than doubled my position today.

[Robthoma]

Accumulation
I will try to double my position tomorrow
Cash waiting in Cash sweep vehicle.
Aloha from Hawaii

[DoubleJackie]

Classic dump fest here.

[Fidel008]

Didn't see anything but with this volume and this accumulation, this is gonna fly during the next few days !!!! Time to accumulate !